NCT00766025View on ClinicalTrials.gov

Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2008

Study Completion Date

February 28, 2009

Conditions
CYP2C19 PoorExtensive Metabolizers
Interventions
DRUG

Rosuvastatin Calcium

single oral dose on days 1, 4, 5, 6, 10-16, 17

Trial Locations (1)

Unknown

Research Site, Taipei

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT00766025 - Study in Taiwanese Subjects Identified as CYP2C19 Poor and Extensive Metabolizers Receiving Rosuvastatin | Biotech Hunter | Biotech Hunter